Cochrane · systematic review · CD012965
Magnesium sulphate for treating acute bronchiolitis in children up to two years of age
Chandelia, S, Kumar, D, Chadha, N, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Acute Respiratory InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
8
No studies
14
Included studies
NR
No studies 14 · 50%Ungraded 6 · 21.4%Very low 7 · 25%Low 1 · 3.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Magnesium sulphate compared with placebo for acute bronchiolitis in children
Population: children up to 18 months old with acute bronchiolitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to recovery Magnesium sulphate vs placebo | no estimate extracted | NR | No studies |
Mortality Magnesium sulphate vs placebo | no estimate extracted | 1 study · 160 participants | Ungraded |
Adverse events Magnesium sulphate vs placebo | no estimate extracted | 1 study · 160 participants | Ungraded |
Duration of hospital stay Magnesium sulphate vs placebo | no estimate extracted | 1 study · 160 participants | Ungraded |
Clinical severity score (CSS) (Wang score; range 0 to 12; higher = poorer outcome)measured at 0 to 24 hoursafter treatment Magnesium sulphate vs placebo | MD 0.13 | 1 study · 160 participants | Very low Downgraded: imprecision, indirectness |
Clinical severity score (CSS) (Wang score; range 0 to 12; higher = poorer outcome)measured at 25 to 48 hoursafter treatment Magnesium sulphate vs placebo | no estimate extracted | 1 study · 160 participants | Very low Downgraded: imprecision, indirectness |
Hospital re‐admission within 30 days of discharge (re‐admissions were reported at 14 days) Magnesium sulphate vs placebo | RR 3.16 [1.2, 8.27] | 1 study · 158 participants | Low Downgraded: imprecision, indirectness |
Magnesium sulphate compared with hypertonic saline for acute bronchiolitis in children
Population: children up to 12 months old with acute bronchiolitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to recovery Magnesium sulphate vs hypertonic saline | no estimate extracted | NR | No studies |
Mortality Magnesium sulphate vs hypertonic saline | no estimate extracted | NR | No studies |
Adverse events Magnesium sulphate vs hypertonic saline | no estimate extracted | NR | No studies |
Duration of hospital stay Magnesium sulphate vs hypertonic saline | MD 0 | 1 study · 220 participants | Very low Downgraded: imprecision, indirectness |
Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured at 0 to 24 hoursafter treatment Magnesium sulphate vs hypertonic saline | no estimate extracted | NR | No studies |
Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured at 25 to 48 hoursafter treatment Magnesium sulphate vs hypertonic saline | MD 0.1 | 1 study · 220 participants | Very low Downgraded: imprecision, indirectness |
Hospital re‐admission within 30 days of discharge Magnesium sulphate vs hypertonic saline | no estimate extracted | NR | No studies |
Magnesium sulphate or magnesium sulphate + salbutamol compared with salbutamol for acute bronchiolitis in children
Population: children from 1 month to 24 months old with acute bronchiolitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to recovery Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol | no estimate extracted | NR | No studies |
Mortality Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol | no estimate extracted | 1 study · 56 participants | Ungraded |
Adverse events Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol | no estimate extracted | 1 study · 56 participants | Ungraded |
Duration of hospital stay Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol | no estimate extracted | 1 study · 56 participants | Ungraded |
Clinical severity score (CSS) (Wang score; range 0 to 12; higher = poorer outcome) measured at 0 to 24 hoursafter treatment Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol | no estimate extracted | NR | No studies |
Clinical severity score (CSS) (Wang score; range 0 to 12; higher = poorer outcome) measured 25 to 48 hoursafter treatment Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol | no estimate extracted | NR | No studies |
Hospital re‐admission within 30 days of discharge Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol | no estimate extracted | NR | No studies |
Magnesium sulphate + epinephrine compared with no treatment or normal saline + epinephrine
Population: children up to 12 months old with acute bronchiolitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to recovery Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine | no estimate extracted | NR | No studies |
Mortality Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine | no estimate extracted | NR | No studies |
Adverse events Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine | no estimate extracted | NR | No studies |
Duration of hospital stay Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine | no estimate extracted | 1 study · 120 participants | Very low Downgraded: imprecision, indirectness |
Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured at 0 to 24 hoursafter treatment Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine | no estimate extracted | 1 study · 120 participants | Very low Downgraded: imprecision, indirectness |
Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured 25 to 48 hoursafter treatment Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine | no estimate extracted | 1 study · 120 participants | Very low Downgraded: imprecision, indirectness |
Hospital re‐admission within 30 days of discharge Magnesium sulphate + epinephrine vs no treatment or normal saline + epinephrine | no estimate extracted | NR | No studies |